Clinical trial
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
NCT00093782 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00093782 |
|---|---|
| Title | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma |
| Official title | A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma |
| Intervention type | Drug, Other |
| Interventions | temsirolimus, laboratory biomarker analysis |
| Enrollment | 36 |
| Start date | Dec 1, 2003 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Oct 8, 2004 |
| Last update posted | Feb 7, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: